Yong Chan Kim

Yong Chan Kim

Auto-generated profile, based on publicly available information

Yong Chan Kim

Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
AZAi-Hong Zhang
Ai-Hong Zhang
JYJeongheon Yoon
Jeongheon Yoon
YKYong Chan Kim
Yong Chan Kim
DSDavid Scott
David Scott
Controlling immune responses in autoimmunity and to biotherapeutics is an unmet need. In hemophilia, for example, up to one third of patients receiving therapeutic factor VIII (FVIII) infusions develop neutralizing Abs termed “inhibitors.” To address this problem in a mouse model of hemophilia A, we used an Ag-specific regulatory T cell (Treg) approach in which we created a novel B cell–targeting chimeric receptor composed of an FVIII Ag domain linked with the CD28-CD3ζ transmembrane and signaling domains. We termed these “BAR” for B cell–targeting Ab receptors. CD4+CD25hiCD127low human Tregs were retrovirally transduced to express a BAR containing the immunodominant FVIII C2 or A2 domains (C2- and A2-BAR). Such BAR-Tregs specifically suppressed the recall Ab response of spleen cultures from FVIII-immunized mice in vitro and completely prevented anti-FVIII Ab development in response to FVIII immunization. Mechanistic studies with purified B cells and T cells from tolerized or control recipients demonstrated that the FVIII-specific B cells were directly suppressed or anergized, whereas the T cell response remained intact. Taken together, we report in this study a successful proof-of-principle strategy using Ag-expressing Tregs to directly target specific B cells, an approach which could be adapted to address other adverse immune responses as well.

13 August 2018 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
YKYong Chan Kim
Yong Chan Kim
KKKee K. Kim
Kee K. Kim
JYJeongheon Yoon
Jeongheon Yoon
DSDavid Scott
David Scott
Ethan ShevachEthan Shevach
Ethan Shevach
Clinical application of Ag-specific T regulatory cells (Tregs) offers promise for the treatment of undesirable immune diseases. To achieve this goal, long-term expansion of Tregs is required to obtain sufficient numbers of cells. However, human Tregs are not stable ex vivo. Therefore, we previously developed an innovative Treg expansion protocol using 25mer-phosphorothioated random oligonucleotides (ODNps25). The addition of ODNps25 successfully resulted in the stabilization of engineered Ag-specific Tregs; however, the mechanism is not fully characterized. We first identified sterile α motif histidine-aspartate–domain containing protein 1 (SAMHD1) as an ODNps25-binding protein using a UV–cross-linking pull-down strategy. SAMHD1 physically interacted with the 3′ untranslated region of Foxp3 mRNA and was translocated from nucleus to cytoplasm after ODNps25 treatment. Importantly, addition of ODNps25 enhanced the interaction of SAMHD1 and Foxp3 mRNA significantly, and this interaction was increased by TCR stimulation. Because ODNps25 binds to the nuclease (HD) domain of SAMHD1, we then established that overexpression of a dNTPase-deficient mutant (D137N) in Tregs significantly stabilized the expression level of the Foxp3 protein. Furthermore, we found that TCR stimulation upregulates phosphorylation of the threonine residue (Thr592), which is a regulatory site to control SAMHD1 activity, and phosphorylation of Thr592 is critical to control SAMHD1 activity to stabilize the expression of Foxp3 and Helios in Tregs. Taken together, we suggest that the interaction of ODNPs25 in HD or phosphorylation of Thr592 by TCR stimulation interferes with nuclease activity of SAMHD1, thereby stabilizing 3′ untranslated region of Foxp3 and Helios mRNAs in long-term culture.

1 March 2008 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
TLTangying (Lily) Lu
Tangying (Lily) Lu
YKYong Chan Kim
Yong Chan Kim
JAJohn Andersson
John Andersson
Ethan ShevachEthan Shevach
Ethan Shevach
It is widely accepted that CD4 + CD25 + Foxp3 + regulatory T cells (Treg) can suppress the activation of CD4 + CD25 − T cells. Although Treg might exert their suppressive effects directly on responder T cells, recent studies have raised the possibility that they may act on dendritic cells (DC). To examine the modulatory effect of Treg on DC, antigen‐specific Foxp3 + Treg were generated in vitro by stimulation of Foxp3 − T cells in the presence of TGF‐β. Peptide‐pulsed DC were then cultured alone, with Treg alone, with naïve T cells (Tn) of the same specificity, or with Treg and Tn. DC cultured in the absence of T cells spontaneously matured in culture as demonstrated by upregulation of CD86 expression. CD86 upregulation was enhanced 3‐fold by culture with Tn and slightly inhibited by co‐culture with Treg alone. The Tn‐induced upregulation of CD86 was completely inhibited by co‐culture with Treg. DC co‐cultured with Tn and Treg also failed to induce the proliferation of Tn both in vitro and in vivo . The inhibitory effects of Treg on DC maturation could be reversed by the addition of SB216763, a glycogen synthase kinase‐3 (GSK3) inhibitor, but not by anti‐IL‐10, ‐TGF‐β, or ‐CTLA4. These studies demonstrate that the immunosuppressive effects of Treg may be mediated via suppression of DC maturation/function and may involve modulation of the GSK‐3/β‐catenin pathway. Supported by NIH/NIAID.

1 May 2023 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
HNHyo Jeong Nam
Hyo Jeong Nam
WLWoochan Lee
Woochan Lee
NBNari Byun
Nari Byun
JYJeong Heon Yoon
Jeong Heon Yoon
YKYong Chan Kim
Yong Chan Kim
HKHyun Je Kim
Hyun Je Kim
Regulatory T cells (Tregs) harness a central role in peripheral immune tolerance. Since its discovery, there have been numerous efforts to dissect the role of Tregs in the context of disease condition. Recently, Treg fields are moving from the academia to industry since many evidences have been accumulated for the potential of treatment of inflammatory disease by administering genetically engineered Tregs. However, in the pre-clinical or clinical trials, this rare cell subset needs to be expanded in ex-vivo condition to achieve a sufficient number for the controlling of the disease. Our group previously established ex-vivo Treg expansion condition with 25 mer oligonucleotide to maintain the stability and function of Tregs. However, non-biased investigations on the perturbation of transcriptomic and epigenetic changes during the culture condition has not been explored. Since cutting edge multiomics tools which can simultaneously profile epigenetic and transcript signatures in a single cell resolution has been commercialized, we adopt 10x multiome technique to investigate our frozen ex-vivo expanded Tregs(eTreg) compared to freshly isolated frozen human Treg(fTreg) from the same donor. Compared to fTreg cells, we have identified a new subset that exists only in the eTreg cells and named it eeTreg. We found that the eeTreg resembles the phenotype of both effector Tregs and tumor-infiltrated Tregs. eeTreg is characterized by a significantly increased expression and chromatin accessibility score of FOXP3, STAT5B, ETS1 and RUNX1, which are known to be the essential transcription factors of regulatory T cell function. In summary, we suggest a novel human treg subset which might be manufactured by manipulating ex-vivo culture condition.